Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13196404 | 0.80 | ALDH1A1 (0.47) | TSHRLMNARAB9AMAPK1 | |
| SCHEMBL7882222 | 0.75 | DPP4 (0.43) | DPP4F2TSHRHTR2ATAAR1 | |
| SCHEMBL15773909 | 0.73 | DPP4 (0.41) | DPP4F2TSHRHTR2ATAAR1 | |
| SCHEMBL4149963 | 0.73 | DPP4 (0.41) | DPP4F2TSHRHTR2ATAAR1 | |
| SCHEMBL8550829 | 0.71 | DPP4 (0.39) | DPP4F2TSHRHTR2ATAAR1 | |
| SCHEMBL6923382 | 0.71 | DPP4 (0.52) | DPP4F2TSHRHTR2ATAAR1 | |
| SCHEMBL377591 | 0.71 | TAAR1 (0.42) | DPP4F2TSHRTAAR1CYP2D6 | |
| SCHEMBL450918 | 0.71 | TAAR1 (0.42) | DPP4F2TSHRTAAR1CYP2D6 | |
| SCHEMBL2406731 | 0.71 | TAAR1 (0.42) | DPP4F2TSHRTAAR1CYP2D6 | |
| SCHEMBL5847868 | 0.69 | HTR2A (0.46) | DPP4F2TSHRHTR2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118955409-A | Cardiac sarcomere inhibitors | 赛特凯恩蒂克公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-112867539-B | Cardiac sarcomere inhibitors | 赛特凯恩蒂克公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9585891-B2 | Alpha hydroxy amides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | MERCK PATENT GMBH (DE) | 2015-09-10 | — | — | US | disclosed |
| EP-2900633-A1 | ALPHA HYDROXY AMIDES | Merck Patent GmbH (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-7645785-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-2038259-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20080021027-A1 | Novel benzimidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | US | disclosed |
| WO-2008000643-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| EP-0921116-B1 | N-(4-carbamimido-phenyl)-glycine amide derivatives | HOFFMANN LA ROCHE (CH) | 2003-06-18 | — | — | EP | disclosed |
| US-6140353-A | USED AS MEDICAMENTS FOR THE TREATMENT AND/OR PREVENTION OF THROMBOSES, APOPLEXY, CARDIAC INFARCTION, INFLAMMATION AND ARTERIOSCLEROSIS OR AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0921116-A1 | N-(4-carbamimido-phenyl)-glycine amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021027-A1 | Novel benzimidazole derivatives | NR1H4, GPR119, GLP1R | DPP4 182/4885F2 2140/4885TSHR 106/4885 |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | HCAR1, NAA40, HCAR2 | DPP4 4657/4885F2 3465/4885TSHR 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.